您的位置: 首页 > 2025年7月 第56卷 第7期 > 文字全文
2023年7月 第38卷 第7期11
目录

妇科恶性肿瘤放疗后阴道损伤的治疗研究进展

Research progress in the treatment of vaginal injury after radiotherapy for gynecological malignancies

来源期刊: 广州医药 | 880-884 发布时间:2025-07-20 收稿时间:2025/8/6 17:38:14 阅读量:34
作者:
关键词:
阴道损伤放射疗法治疗研究进展
vaginal injuryradiation therapytreatmentresearch progress
DOI:
10. 20223 / j. cnki. 1000-8535. 2025. 07 003
收稿时间:
2024-08-31 
修订日期:
 
接收日期:
 
引用总数:
0  
        放射治疗(放疗)可以提高妇科恶性肿瘤患者的总体生存率,降低复发率,增加手术机会。但肿瘤周围的健康组织不可避免地会进入电离辐射区域从而导致阴道狭窄、缩短和失去弹性,文章结合近年来国内外的放疗后阴道损伤治疗方式进行综述,总结分析治疗的优缺点,旨在为放疗后阴道损伤的临床治疗提供帮助。
       Radiotherapy can improve the overall survival rate,reduce the  recurrence  rate and increase the chance of surgery in patients with gynecological malignant tumors.However,the healthy tissue around the tumor can inevitably be included the ionizing radiation area,resulting in vaginal stenosis,shortening and loss of elasticity.This paper reviews the treatment methods of post-radiotherapy vaginal injury at home and abroad in recent years,to summarize and analyze theadvantages and disadvantages of treatment,aiming to provide help for the clinical treatment of post-radiotherapy vaginal injury.
       放射治疗(放疗)是治疗妇科恶性肿瘤不可或缺的重要组成部分,超过 70% 的妇科恶性肿瘤患者的治疗方案中都包括这一组成部分,且总体治疗效率达到了30%~50%[1]。放射治疗可以提高患者的总体生存率,降低复发率,增加手术机会,减少术中和术后并发症,其治疗效果明[2]。但是肿瘤周围的健康组织不可避免地会进入电离辐射区域从而导致阴道狭窄、缩短和失去弹性。这严重影响临床疗效,并且与性功能障碍有关,降低患者的生活质量。因此选择合适的治疗方法至关重要,笔者对近年来国内外的放疗后阴道损伤治疗方式进行综述,总结治疗的优缺点,旨在为放疗后阴道损伤的临床治疗提供参考。

1  放疗后阴道损伤的概述

       在放射治疗中,外阴及阴道黏膜、结缔组织、小血管受到损伤,致使上皮细胞剥脱,外阴和阴道上皮细胞快速更新促进外层未分裂细胞的脱落,从而导致上皮更易受到放射损伤。此外,放疗会破坏阴道微环境,造成阴道感染和粘连,进一步加重阴道放射性损伤[3]。阴道放射性损伤可以分为放射治疗过程中的急性损伤和治疗结束后几个月的晚期损伤。急性阴道损伤包括阴道红斑、脱皮、阴道炎症,或者出现溃疡和坏死,甚至瘘管形成。晚期损伤主要表现为阴道干涩、狭窄、缩短,以及性交疼痛、出血[4]。放疗后阴道损伤的发生率和严重程度与患者年龄、吸烟史、肿瘤分期和治疗范围、辐射剂量以及放射治疗的方式有关。一项研究指出,对于接受盆腔或阴道放疗的宫颈癌患者,年龄>50岁会增加阴道损伤的风险[5]。吸烟已被确定为阴道损伤的一个重要危险因素。一项对阴道癌明确放射治疗后的回顾性研究显示,当前吸烟者、过去6个月戒烟者和从不吸烟者的5年并发症风险分别为25%、18%和5%[6]。修雨婷等[7]在211例宫颈癌放疗治疗中发现,FIGO分期>Ⅲb期者因其所需要的照射剂量更大及患者免疫能力、抵抗能力较弱,在开展体外放疗联合腔内后装放疗时,其盆腔器官更易发生放射性损伤。莫杏能等[8]研究发现,后装放疗A点剂量>24 Gy出现阴道放射性损伤的危险性是剂量≤24 Gy患者的3.167倍。美国NCCN宫颈癌治疗指南指出,A点总剂量在根治性治疗中要求达到80~85 Gy,即腔内后装放疗剂量达到24~30 Gy,但剂量较高可增加放射性损伤发生率[9]。阴道放射性损伤的临床表现为阴道干燥、出血、疼痛,阴道狭窄、溃疡、黏膜萎缩,性交疼痛或性交困难,而对于相对年轻患者来说性交问题是影响生活质量的重要原因[10]。因此选择合适的治疗措施十分必要。

2  放疗后阴道损伤的治疗

2.1  肿瘤复发的评估

      在处理放疗后阴道损伤时要关注损伤组织的变化,阴道组织坏死可能与肿瘤复发并存,若肿瘤复发时则需要对肿瘤进行处理。活组织检查(活检)可以提供明确的诊断,然而,切除组织会加重坏死和继发瘘管形成。因此,是否进行活检是基于对肿瘤复发可能性的临床判断。

2.2  防治感染

      充足的血液供应对于因慢性组织缺血而导致的损伤愈合来说具有重要作用。可以通过适当增加营养、调整糖尿病患者血糖水平、戒烟来改善局部血液供应[6]。阴道口因与直肠肛门解剖位置紧邻,被粪便污染可能性大,坏死组织是细菌的营养来源,因此潜在的感染风险增加,应进行用温和肥皂或坐浴清洁外阴等措施以去除局部刺激物(例如尿液)。此外,为避免不可逆不良反应的发生,放疗中及放疗后2年内均需要进行常规阴道冲洗。阴道冲洗可有效清除坏死脱落的组织细胞。目前多数推荐清水冲洗,但有研究发现采用0.2%碘伏溶液冲洗阴道及外阴7周,在杀灭病原菌的同时亦不会破坏阴道自净功能及酸碱度,并可促进局部血液循环、改善阴道营养状态、防止继发感染[11]。有多项研究使用不同中药冲洗液。魏文婷等[12]使用苦参、蛇床子、蒲公英等中药汤剂冲洗阴道效果明显优于高锰酸钾溶液。周雯等[13]认为活血化瘀、清热燥湿的汤药可以促进阴道黏膜上皮细胞的愈合、炎症吸收及溃疡修复。亦有研究使用中医特色疗法,效果显著。齐子威等[14]使用阴道填塞中药溻渍法效果明显优于三乙醇乳膏,并且延长了阴道内药物作用时间。

2.3  阴道扩张器治疗

       放疗后阴道损伤使用扩张器治疗的理念是尽早分离和预防阴道黏膜壁之间的粘连,阴道扩张器还可以拉伸阴道组织和阴道管,刺激上皮细胞生长,防止环状纤维化和弹性变性[15]。相关研究发现,阴道扩张器与妇科和肛门直肠癌患者盆腔放疗后严重阴道狭窄风险降低之间存在显著相关[16]。尽管没有高级别证据,但许多评论和指南支持盆腔放疗后使用阴道扩张器治疗,其仍然是普遍认可的阴道狭窄预防措施,并广泛应用于临床实践[17]。目前阴道扩张器治疗缺乏普遍共识,包括扩张器治疗的规律性、开始使用时间、持续时间和扩张器尺寸、插入方法以及有性生活的女性是否需要阴道扩张器等。2020年新西兰一项调查研究认为无论有无性活动,均建议使用扩张器,且建议放疗结束2周内或2周以后使用阴道扩张器,使用时间从6个月至超过36个月不等[18]Charatsi等[19]建议在放射治疗后不超过3个月开始阴道扩张,每周至少2~3次,每次持续10~15 min,持续12个月。但此结论需要更大规模的临床试验证明。2019年巴西版共识建议每次应持续至少5~10 min,每周2~3次,持续时间不限。但其并未就何时开始使用阴道扩张器达成共识[20]。阴道扩张器材料有塑料、硅胶、乳胶、医用级材料等。用于制造扩张器的材料从未在放射治疗相关的阴道狭窄的背景下进行过严格比较。目前塑料材质的扩张器使用最为广泛[21]。另外,医生应指导患者如何使用阴道扩张器,建议患者在开始扩张前后排尿。然后应将患者置于半卧位,在镜子的辅助下医生向患者解释生殖器解剖,向患者显示大阴唇、小阴唇、阴蒂、尿路、阴道远端和处女膜的位置。医生应演示置入阴道扩张器的过程,如果在置入过程患者感到疼痛,可以在使用阴道扩张器治疗前20分钟将利多卡因凝胶局部涂抹在阴道口上以减少疼痛[22]

2.4  透明质酸治疗

       近年来对透明质酸(hyaluronic acid,HA)的研究越来越多,其应用范围也越来越广。HA是一种多糖,是参与组织修复和再生过程的糖胺聚糖的一部分,同时透明质酸也是细胞外基质的重要组成部分,通过维持足量的水合作用帮助细胞迁移,参与修复过程。由于其高分子质量,透明质酸在皮肤或黏膜上使用时不被吸收,从而形成一层可穿透的黏弹性外表面薄膜,这种网状膜保持了黏膜中的水分,保持了健康组织的光滑、紧张度和弹性[23]。在阴道放射性损伤治疗中,HA具有高安全水平、无禁忌证,且能与其他药物相互作用。已有众多含有透明质酸的产品应用到阴道放疗后损伤的治疗中,并且取得了良好效果。Ribeiro等[24]检索2009年至2022年间HA治疗妇科癌症患者放射毒性的文章发现,HA已以多种剂型(保湿凝胶、阴道胚珠、隔离凝胶、阴道栓剂)应用于临床实践,且能有效改善阴道萎缩、干燥、狭窄、出血、粘连、性交困难等问题。Carter[25]研究发现,HA可改善癌症幸存者的外阴阴道健康及性功能,且每周接受HA治疗3~5次效果更佳。

2.5  高压氧治疗

       高压氧治疗是通过增加组织氧合促进伤口愈合,直接增强中性粒细胞杀菌活性,刺激血管生成和成纤维细胞增殖来发挥作用[6]。高压氧治疗的绝对禁忌证是张力性气胸。相对禁忌证包括阻塞性肺疾病、近期的耳廓或胸廓手术以及幽闭恐惧症。潜在的不良反应包括糖尿病患者的低血糖、眼睛屈光度改变、气压损伤和氧介导癫痫发作[6]一项纳入了7例年龄在18~90岁之间女性接受盆腔癌放射治疗并伴有软组织放射性坏死的回顾性病例报告,收集了接受高压氧治疗的压力、时间和总治疗量数据资料。其主要结果为放射性坏死的改善,次要结果是盆腔疼痛、镇痛需求和阴道出血的减少。其中6例接受高压氧治疗的放射性阴道坏死患者中有5例(83%)至少在一项结果测量中得到改善[26]。这些结果增加了现有数据,支持在无禁忌证的有放射治疗引起的阴道软组织坏死相关症状的患者中使用高压氧治疗。但该回顾报告样本量少,未来仍需前瞻性研究和严格报告高压氧用于治疗放射性阴道损伤的结果。

2.6  激光治疗

       近年来阴道内激光治疗主要集中在性健康和治疗绝经后阴道萎缩所产生的症状方面,在改善性欲、性交困难、阴道干燥等方面起到作用。特别是CO2激光能够激活急性热消融或非消融效应,刺激成熟的胶原成分、成纤维细胞增殖和细胞外基质的合成,从而增加阴道壁的弹性和水合作用[27]。Perrone等[28]调查了43例在接受放射治疗骨盆肿瘤后患有严重阴道缩短、狭窄和萎缩的女性。每隔1个月安排3次阴道内非消融性CO2激光治疗,所有操作均可很好耐受。在最后1次阴道激光治疗6个月后,检查人员观察到阴道长度和阴道健康指数逐渐增加。作者认为阴道内激光治疗对于盆腔放疗后女性,是一种有效的放射性阴道损伤治疗方法,但还需要更多的随机临床试验来证实这一结果。

2.7  心理干预

       随着癌症患者生存期的延长及疾病年轻化发展趋势[28],生存质量越来越引起医务工作人员的重视。接受放疗的恶性肿瘤患者常伴随焦虑抑郁、性生活质量下降,这大大降低了患者生存质量。目前我国肿瘤放射科医生给予患者性生活指导建议不足[29]。医生对患者及其性伴侣进行性健康知识宣教和性生活指导是有必要的。心理压力较大或处于焦虑抑郁状态的患者应积极进行心理治疗,必要时使用药物治疗。我国正念干预专家共识指出正念治疗作为恶性肿瘤的辅助治疗,可以明显改善患者情绪状态,增加幸福感[30]。此外,医护人员根据患者疾病进程进行时机赋能教育,可消除其紧张焦虑感受,提高患者社会适应性与应对能力,且能明显增加抑郁患者药物依从性。

3  总结与展望

       放疗作为妇科恶性肿瘤的有效治疗措施,可以提高患者的总体生存率。但放疗后出现的阴道损伤可能给患者身心健康和后续生活质量带来重要影响,这些是临床医生必须面对和亟待解决的问题。放疗后阴道损伤的发生受到多种因素影响,当发生阴道损伤时应该排除是否肿瘤复发,应考虑应用阴道冲洗、抗生素、高压氧进行保守治疗。当保守措施无效时,可能需要激光治疗或手术清创以促进愈合。在整个过程中,需要仔细的管理和密切的随访,以确保症状的缓解。未来也需要进行下一阶段的随机临床试验,比较和分析不同的治疗方案和策略,为放疗后阴道损伤的治疗提供高质量的证据。
1、SUKHINA%E2%80%83O%E2%80%83M%EF%BC%8CNEMALTSOVA%E2%80%83K%E2%80%83V%EF%BC%8CPANOV%E2%80%83O%E2%80%83V%EF%BC%8E%0ALate%E2%80%83%20radiation%E2%80%83toxicity%E2%80%83after%E2%80%83%20radical%E2%80%83%20radiotherapy%E2%80%83for%E2%80%83%0Agenital%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EProbl%E2%80%83Radiac%E2%80%83Med%E2%80%83Radiobiol%EF%BC%8C%0A2020%EF%BC%8825%EF%BC%89%EF%BC%9A130-147%EF%BC%8ESUKHINA%E2%80%83O%E2%80%83M%EF%BC%8CNEMALTSOVA%E2%80%83K%E2%80%83V%EF%BC%8CPANOV%E2%80%83O%E2%80%83V%EF%BC%8E%0ALate%E2%80%83%20radiation%E2%80%83toxicity%E2%80%83after%E2%80%83%20radical%E2%80%83%20radiotherapy%E2%80%83for%E2%80%83%0Agenital%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8EProbl%E2%80%83Radiac%E2%80%83Med%E2%80%83Radiobiol%EF%BC%8C%0A2020%EF%BC%8825%EF%BC%89%EF%BC%9A130-147%EF%BC%8E
2、CHARGARI%E2%80%83C%EF%BC%8CPEIGNAUX%E2%80%83K%EF%BC%8CESCANDE%E2%80%83A%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8ERadiotherapy%E2%80%83of%E2%80%83cervical%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83%0ARadiother%EF%BC%8C2022%EF%BC%8C26%EF%BC%881-2%EF%BC%89%EF%BC%9A298-308%EF%BC%8ECHARGARI%E2%80%83C%EF%BC%8CPEIGNAUX%E2%80%83K%EF%BC%8CESCANDE%E2%80%83A%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8ERadiotherapy%E2%80%83of%E2%80%83cervical%E2%80%83cancer%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancer%E2%80%83%0ARadiother%EF%BC%8C2022%EF%BC%8C26%EF%BC%881-2%EF%BC%89%EF%BC%9A298-308%EF%BC%8E
3、高欢,高莹,祝晓莲,等.子宫恶性肿瘤的放射治疗对阴道微生物的影响[J].中国妇产科临床杂志,2019,20(6):573-574.高欢,高莹,祝晓莲,等.子宫恶性肿瘤的放射治疗对阴道微生物的影响[J].中国妇产科临床杂志,2019,20(6):573-574.
4、佘宇佳,叶明侠,孟元光.宫颈癌放疗后阴道损伤的研究进展[J].解放军医学院学报,2020,41(2):196-198.佘宇佳,叶明侠,孟元光.宫颈癌放疗后阴道损伤的研究进展[J].解放军医学院学报,2020,41(2):196-198.
5、郭旗,许碧纯,刘叶红,等.宫颈癌术后调强放射治疗的早期不良反应及影响因素[J].中华放射医学与防护杂志,2020,40(5):365-371.郭旗,许碧纯,刘叶红,等.宫颈癌术后调强放射治疗的早期不良反应及影响因素[J].中华放射医学与防护杂志,2020,40(5):365-371.
6、JIA%E2%80%83A%E2%80%83Y%EF%BC%8CVISWANATHAN%E2%80%83A%E2%80%83N%EF%BC%8EVaginal%E2%80%83necrosis%EF%BC%9A%0AA%E2%80%83rare%E2%80%83late%E2%80%83toxicity%E2%80%83after%E2%80%83radiation%E2%80%83therapy%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AGynecol%E2%80%83Oncol%EF%BC%8C2021%EF%BC%8C160%EF%BC%882%EF%BC%89%EF%BC%9A602-609%EF%BC%8EJIA%E2%80%83A%E2%80%83Y%EF%BC%8CVISWANATHAN%E2%80%83A%E2%80%83N%EF%BC%8EVaginal%E2%80%83necrosis%EF%BC%9A%0AA%E2%80%83rare%E2%80%83late%E2%80%83toxicity%E2%80%83after%E2%80%83radiation%E2%80%83therapy%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AGynecol%E2%80%83Oncol%EF%BC%8C2021%EF%BC%8C160%EF%BC%882%EF%BC%89%EF%BC%9A602-609%EF%BC%8E
7、修雨婷,孟凡旭,欧健,等.211例宫颈癌根治性放疗的预后分析[J].中华放射医学与防护杂志,2019,39(10):762-767.修雨婷,孟凡旭,欧健,等.211例宫颈癌根治性放疗的预后分析[J].中华放射医学与防护杂志,2019,39(10):762-767.
8、莫杏能,陆秋云,唐敏,等.宫颈癌根治性放疗致阴道放射性损伤的危险因素调查及防护[J].临床护理杂志,2021,20(2):2-5.莫杏能,陆秋云,唐敏,等.宫颈癌根治性放疗致阴道放射性损伤的危险因素调查及防护[J].临床护理杂志,2021,20(2):2-5.
9、ABU-RUSTUM%E2%80%83N%E2%80%83R%EF%BC%8CYASHAR%E2%80%83C%E2%80%83M%EF%BC%8CBEAN%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ANCCN%E2%80%83guidelines%E2%80%83insights%EF%BC%9ACervical%E2%80%83cancer%EF%BC%8Cversion%E2%80%831%EF%BC%8E%0A2020%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Natl%E2%80%83Compr%E2%80%83Canc%E2%80%83Netw%EF%BC%8C2020%EF%BC%8C18%0A%EF%BC%886%EF%BC%89%EF%BC%9A660-666%EF%BC%8EABU-RUSTUM%E2%80%83N%E2%80%83R%EF%BC%8CYASHAR%E2%80%83C%E2%80%83M%EF%BC%8CBEAN%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ANCCN%E2%80%83guidelines%E2%80%83insights%EF%BC%9ACervical%E2%80%83cancer%EF%BC%8Cversion%E2%80%831%EF%BC%8E%0A2020%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Natl%E2%80%83Compr%E2%80%83Canc%E2%80%83Netw%EF%BC%8C2020%EF%BC%8C18%0A%EF%BC%886%EF%BC%89%EF%BC%9A660-666%EF%BC%8E
10、奚兰花,张小萍.循证护理对宫颈癌患者放疗后并发症与生活质量的影响[J].护理实践与研究,2019,16(13):101-103.奚兰花,张小萍.循证护理对宫颈癌患者放疗后并发症与生活质量的影响[J].护理实践与研究,2019,16(13):101-103.
11、张恺铄,刘孜,汪涛,等.阴道放射性损伤研究进展[J].中华放射肿瘤学杂志,2019,28(1):69-73.张恺铄,刘孜,汪涛,等.阴道放射性损伤研究进展[J].中华放射肿瘤学杂志,2019,28(1):69-73.
12、魏文婷,赵林,赵凤菊,等.中药阴道冲洗液治疗放射性阴道炎的临床观察[J].中医临床研究,2021,13(18):119-121.魏文婷,赵林,赵凤菊,等.中药阴道冲洗液治疗放射性阴道炎的临床观察[J].中医临床研究,2021,13(18):119-121.
13、周雯,高文强,关婷,等.中药冲洗剂预防宫颈癌放疗放射性损伤的临床观察[J].中医药导报,2019,25(23):67-69.周雯,高文强,关婷,等.中药冲洗剂预防宫颈癌放疗放射性损伤的临床观察[J].中医药导报,2019,25(23):67-69.
14、齐子威,袁香坤,刘琼.阴道填塞溻渍法治疗宫颈癌近距离放疗后阴道损伤的疗效观察[J].中医肿瘤学杂志,2024,6(3):37-42.齐子威,袁香坤,刘琼.阴道填塞溻渍法治疗宫颈癌近距离放疗后阴道损伤的疗效观察[J].中医肿瘤学杂志,2024,6(3):37-42.
15、STAHL%E2%80%83J%E2%80%83M%EF%BC%8CQIAN%E2%80%83J%E2%80%83M%EF%BC%8CTIEN%E2%80%83C%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EExtended%E2%80%83%0Aduration%E2%80%83%20of%E2%80%83%20dilator%E2%80%83%20use%E2%80%83%20beyond%E2%80%83%201%E2%80%83%20year%E2%80%83%20may%E2%80%83%20reduce%E2%80%83%0Avaginal%E2%80%83%20stenosis%E2%80%83%20after%E2%80%83intravaginal%E2%80%83%20high-dose-rate%E2%80%83%0Abrachytherapy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2019%EF%BC%8C%0A27%EF%BC%884%EF%BC%89%EF%BC%9A1425-1433%EF%BC%8ESTAHL%E2%80%83J%E2%80%83M%EF%BC%8CQIAN%E2%80%83J%E2%80%83M%EF%BC%8CTIEN%E2%80%83C%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EExtended%E2%80%83%0Aduration%E2%80%83%20of%E2%80%83%20dilator%E2%80%83%20use%E2%80%83%20beyond%E2%80%83%201%E2%80%83%20year%E2%80%83%20may%E2%80%83%20reduce%E2%80%83%0Avaginal%E2%80%83%20stenosis%E2%80%83%20after%E2%80%83intravaginal%E2%80%83%20high-dose-rate%E2%80%83%0Abrachytherapy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2019%EF%BC%8C%0A27%EF%BC%884%EF%BC%89%EF%BC%9A1425-1433%EF%BC%8E
16、AMIES%E2%80%83OELSCHLAGER%E2%80%83A%E2%80%83M%EF%BC%8CDEBIEC%E2%80%83K%EF%BC%8EVaginal%E2%80%83%0Adilator%E2%80%83therapy%EF%BC%9AA%E2%80%83guide%E2%80%83for%E2%80%83%20providers%E2%80%83for%E2%80%83assessing%E2%80%83%0Areadiness%E2%80%83and%E2%80%83supporting%E2%80%83patients%E2%80%83through%E2%80%83the%E2%80%83process%E2%80%83%0Asuccessfully%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Pediatr%E2%80%83Adolesc%E2%80%83Gynecol%EF%BC%8C%0A2019%EF%BC%8C32%EF%BC%884%EF%BC%89%EF%BC%9A354-358%EF%BC%8EAMIES%E2%80%83OELSCHLAGER%E2%80%83A%E2%80%83M%EF%BC%8CDEBIEC%E2%80%83K%EF%BC%8EVaginal%E2%80%83%0Adilator%E2%80%83therapy%EF%BC%9AA%E2%80%83guide%E2%80%83for%E2%80%83%20providers%E2%80%83for%E2%80%83assessing%E2%80%83%0Areadiness%E2%80%83and%E2%80%83supporting%E2%80%83patients%E2%80%83through%E2%80%83the%E2%80%83process%E2%80%83%0Asuccessfully%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Pediatr%E2%80%83Adolesc%E2%80%83Gynecol%EF%BC%8C%0A2019%EF%BC%8C32%EF%BC%884%EF%BC%89%EF%BC%9A354-358%EF%BC%8E
17、DAMAST%E2%80%83S%EF%BC%8CJEFFERY%E2%80%83D%E2%80%83D%EF%BC%8CSON%E2%80%83C%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ALiterature%E2%80%83%20review%E2%80%83of%E2%80%83vaginal%E2%80%83stenosis%E2%80%83and%E2%80%83dilator%E2%80%83use%E2%80%83in%E2%80%83%0Aradiation%E2%80%83oncology%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPract%E2%80%83Radiat%E2%80%83Oncol%EF%BC%8C2019%EF%BC%8C%0A9%EF%BC%886%EF%BC%89%EF%BC%9A479-491%EF%BC%8EDAMAST%E2%80%83S%EF%BC%8CJEFFERY%E2%80%83D%E2%80%83D%EF%BC%8CSON%E2%80%83C%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ALiterature%E2%80%83%20review%E2%80%83of%E2%80%83vaginal%E2%80%83stenosis%E2%80%83and%E2%80%83dilator%E2%80%83use%E2%80%83in%E2%80%83%0Aradiation%E2%80%83oncology%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPract%E2%80%83Radiat%E2%80%83Oncol%EF%BC%8C2019%EF%BC%8C%0A9%EF%BC%886%EF%BC%89%EF%BC%9A479-491%EF%BC%8E
18、SUMMERFIELD%E2%80%83J%EF%BC%8CLEONG%E2%80%83A%EF%BC%8EManagement%E2%80%83%20of%E2%80%83%0Aradiation%E2%80%83therapy-induced%E2%80%83%20vaginal%E2%80%83%20adhesions%E2%80%83%20and%E2%80%83%0Astenosis%EF%BC%9AA%E2%80%83New%E2%80%83Zealand%E2%80%83survey%E2%80%83of%E2%80%83current%E2%80%83practice%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Med%E2%80%83Radiat%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C67%EF%BC%882%EF%BC%89%EF%BC%9A128-%0A133%EF%BC%8ESUMMERFIELD%E2%80%83J%EF%BC%8CLEONG%E2%80%83A%EF%BC%8EManagement%E2%80%83%20of%E2%80%83%0Aradiation%E2%80%83therapy-induced%E2%80%83%20vaginal%E2%80%83%20adhesions%E2%80%83%20and%E2%80%83%0Astenosis%EF%BC%9AA%E2%80%83New%E2%80%83Zealand%E2%80%83survey%E2%80%83of%E2%80%83current%E2%80%83practice%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Med%E2%80%83Radiat%E2%80%83Sci%EF%BC%8C2020%EF%BC%8C67%EF%BC%882%EF%BC%89%EF%BC%9A128-%0A133%EF%BC%8E
19、CHARATSI%E2%80%83D%EF%BC%8CVANAKARA%E2%80%83P%EF%BC%8CEVAGGELOPOULOU%E2%80%83%0AE%EF%BC%8Cet%E2%80%83al%EF%BC%8EVaginal%E2%80%83%20dilator%E2%80%83%20use%E2%80%83%20to%E2%80%83%20promote%E2%80%83%20sexual%E2%80%83wellbeing%E2%80%83after%E2%80%83%20radiotherapy%E2%80%83in%E2%80%83gynecological%E2%80%83cancer%E2%80%83%0Asurvivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMedicine%EF%BC%88Baltimore%EF%BC%89%EF%BC%8C2022%EF%BC%8C101%0A%EF%BC%884%EF%BC%89%EF%BC%9Ae28705%EF%BC%8ECHARATSI%E2%80%83D%EF%BC%8CVANAKARA%E2%80%83P%EF%BC%8CEVAGGELOPOULOU%E2%80%83%0AE%EF%BC%8Cet%E2%80%83al%EF%BC%8EVaginal%E2%80%83%20dilator%E2%80%83%20use%E2%80%83%20to%E2%80%83%20promote%E2%80%83%20sexual%E2%80%83wellbeing%E2%80%83after%E2%80%83%20radiotherapy%E2%80%83in%E2%80%83gynecological%E2%80%83cancer%E2%80%83%0Asurvivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMedicine%EF%BC%88Baltimore%EF%BC%89%EF%BC%8C2022%EF%BC%8C101%0A%EF%BC%884%EF%BC%89%EF%BC%9Ae28705%EF%BC%8E
20、MATOS%E2%80%83S%E2%80%83R%E2%80%83L%EF%BC%8CLUCAS%E2%80%83ROCHA%E2%80%83CUNHA%E2%80%83M%EF%BC%8C%0APODGAEC%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EConsensus%E2%80%83for%E2%80%83vaginal%E2%80%83%20stenosis%E2%80%83%0Aprevention%E2%80%83in%E2%80%83patients%E2%80%83submitted%E2%80%83to%E2%80%83pelvic%E2%80%83radiotherapy%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPLoS%E2%80%83One%EF%BC%8C2019%EF%BC%8C14%EF%BC%888%EF%BC%89%EF%BC%9Ae0221054%EF%BC%8EMATOS%E2%80%83S%E2%80%83R%E2%80%83L%EF%BC%8CLUCAS%E2%80%83ROCHA%E2%80%83CUNHA%E2%80%83M%EF%BC%8C%0APODGAEC%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8EConsensus%E2%80%83for%E2%80%83vaginal%E2%80%83%20stenosis%E2%80%83%0Aprevention%E2%80%83in%E2%80%83patients%E2%80%83submitted%E2%80%83to%E2%80%83pelvic%E2%80%83radiotherapy%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPLoS%E2%80%83One%EF%BC%8C2019%EF%BC%8C14%EF%BC%888%EF%BC%89%EF%BC%9Ae0221054%EF%BC%8E
21、%E2%80%83%20MORGAN%E2%80%83O%EF%BC%8CLOPEZ%E2%80%83M%E2%80%83D%EF%BC%8CMARTINEZ%E2%80%83A%E2%80%83J%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ASystematic%E2%80%83%20review%E2%80%83of%E2%80%83comparisons%E2%80%83between%E2%80%83plastic%E2%80%83and%E2%80%83%0Asilicone%E2%80%83dilators%EF%BC%9ARevealing%E2%80%83a%E2%80%83knowledge%E2%80%83gap%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESex%E2%80%83%0AMed%E2%80%83Rev%EF%BC%8C2022%EF%BC%8C10%EF%BC%884%EF%BC%89%EF%BC%9A513-519%EF%BC%8E%E2%80%83%20MORGAN%E2%80%83O%EF%BC%8CLOPEZ%E2%80%83M%E2%80%83D%EF%BC%8CMARTINEZ%E2%80%83A%E2%80%83J%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ASystematic%E2%80%83%20review%E2%80%83of%E2%80%83comparisons%E2%80%83between%E2%80%83plastic%E2%80%83and%E2%80%83%0Asilicone%E2%80%83dilators%EF%BC%9ARevealing%E2%80%83a%E2%80%83knowledge%E2%80%83gap%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESex%E2%80%83%0AMed%E2%80%83Rev%EF%BC%8C2022%EF%BC%8C10%EF%BC%884%EF%BC%89%EF%BC%9A513-519%EF%BC%8E
22、FACCHIN%E2%80%83F%EF%BC%8CRESTELLI%E2%80%83E%EF%BC%8CVERCELLINI%E2%80%83P%EF%BC%8E%0AVaginal%E2%80%83dilator%E2%80%83therapy%EF%BC%9AFurther%E2%80%83%20suggestions%E2%80%83%20for%E2%80%83%0Aproviders%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Pediatr%E2%80%83Adolesc%E2%80%83Gynecol%EF%BC%8C2020%EF%BC%8C%0A33%EF%BC%883%EF%BC%89%EF%BC%9A314%EF%BC%8EFACCHIN%E2%80%83F%EF%BC%8CRESTELLI%E2%80%83E%EF%BC%8CVERCELLINI%E2%80%83P%EF%BC%8E%0AVaginal%E2%80%83dilator%E2%80%83therapy%EF%BC%9AFurther%E2%80%83%20suggestions%E2%80%83%20for%E2%80%83%0Aproviders%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Pediatr%E2%80%83Adolesc%E2%80%83Gynecol%EF%BC%8C2020%EF%BC%8C%0A33%EF%BC%883%EF%BC%89%EF%BC%9A314%EF%BC%8E
23、NAPPI%E2%80%83R%E2%80%83E%EF%BC%8CMARTELLA%E2%80%83S%EF%BC%8CALBANI%E2%80%83F%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AHyaluronic%E2%80%83acid%EF%BC%9AA%E2%80%83valid%E2%80%83therapeutic%E2%80%83option%E2%80%83for%E2%80%83early%E2%80%83%0Amanagement%E2%80%83of%E2%80%83genitourinary%E2%80%83%E2%80%83syndrome%E2%80%83of%E2%80%83menopause%E2%80%83%0Ain%E2%80%83cancer%E2%80%83survivors%3F%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHealthcare%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2022%EF%BC%8C10%EF%BC%888%EF%BC%89%EF%BC%9A1528%EF%BC%8ENAPPI%E2%80%83R%E2%80%83E%EF%BC%8CMARTELLA%E2%80%83S%EF%BC%8CALBANI%E2%80%83F%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AHyaluronic%E2%80%83acid%EF%BC%9AA%E2%80%83valid%E2%80%83therapeutic%E2%80%83option%E2%80%83for%E2%80%83early%E2%80%83%0Amanagement%E2%80%83of%E2%80%83genitourinary%E2%80%83%E2%80%83syndrome%E2%80%83of%E2%80%83menopause%E2%80%83%0Ain%E2%80%83cancer%E2%80%83survivors%3F%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHealthcare%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2022%EF%BC%8C10%EF%BC%888%EF%BC%89%EF%BC%9A1528%EF%BC%8E
24、%E2%80%83%20RIBEIRO%E2%80%83L%E2%80%83D%E2%80%83S%EF%BC%8CSILVEIRA%E2%80%83R%E2%80%83C%E2%80%83C%E2%80%83P%EF%BC%8CVASQUES%E2%80%83C%E2%80%83%0AI%EF%BC%8Cet%E2%80%83al%EF%BC%8EHyaluronic%E2%80%83acid%E2%80%83to%E2%80%83manage%E2%80%83%20radiotoxicities%E2%80%83in%E2%80%83%0Agynecological%E2%80%83cancer%E2%80%83patients%EF%BC%9AA%E2%80%83scoping%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ASupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2024%EF%BC%8C32%EF%BC%887%EF%BC%89%EF%BC%9A439%EF%BC%8E%E2%80%83%20RIBEIRO%E2%80%83L%E2%80%83D%E2%80%83S%EF%BC%8CSILVEIRA%E2%80%83R%E2%80%83C%E2%80%83C%E2%80%83P%EF%BC%8CVASQUES%E2%80%83C%E2%80%83%0AI%EF%BC%8Cet%E2%80%83al%EF%BC%8EHyaluronic%E2%80%83acid%E2%80%83to%E2%80%83manage%E2%80%83%20radiotoxicities%E2%80%83in%E2%80%83%0Agynecological%E2%80%83cancer%E2%80%83patients%EF%BC%9AA%E2%80%83scoping%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ASupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2024%EF%BC%8C32%EF%BC%887%EF%BC%89%EF%BC%9A439%EF%BC%8E
25、CARTER%E2%80%83J%EF%BC%8CBASER%E2%80%83R%E2%80%83E%EF%BC%8CGOLDFRANK%E2%80%83D%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83single-arm%EF%BC%8Cprospective%E2%80%83trial%E2%80%83investigating%E2%80%83the%E2%80%83%0Aeffectiveness%E2%80%83of%E2%80%83a%E2%80%83%20non-hormonal%E2%80%83vaginal%E2%80%83moisturizer%E2%80%83%0Acontaining%E2%80%83hyaluronic%E2%80%83acid%E2%80%83in%E2%80%83postmenopausal%E2%80%83cancer%E2%80%83%0Asurvivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2021%EF%BC%8C29%0A%EF%BC%881%EF%BC%89%EF%BC%9A311-322%EF%BC%8ECARTER%E2%80%83J%EF%BC%8CBASER%E2%80%83R%E2%80%83E%EF%BC%8CGOLDFRANK%E2%80%83D%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83single-arm%EF%BC%8Cprospective%E2%80%83trial%E2%80%83investigating%E2%80%83the%E2%80%83%0Aeffectiveness%E2%80%83of%E2%80%83a%E2%80%83%20non-hormonal%E2%80%83vaginal%E2%80%83moisturizer%E2%80%83%0Acontaining%E2%80%83hyaluronic%E2%80%83acid%E2%80%83in%E2%80%83postmenopausal%E2%80%83cancer%E2%80%83%0Asurvivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESupport%E2%80%83Care%E2%80%83Cancer%EF%BC%8C2021%EF%BC%8C29%0A%EF%BC%881%EF%BC%89%EF%BC%9A311-322%EF%BC%8E
26、MCGLYNN%E2%80%83J%EF%BC%8CHEYBOER%E2%80%83M%EF%BC%8ESuccessful%E2%80%83treatment%E2%80%83%0Aof%E2%80%83%20radiation-induced%E2%80%83vaginal%E2%80%83soft%E2%80%83tissue%E2%80%83%20radionecrosis%E2%80%83%0Awith%E2%80%83%E2%80%83HBO2%EF%BC%BBJ%EF%BC%BD%EF%BC%8EUndersea%E2%80%83Hyperb%E2%80%83Med%EF%BC%8C2023%EF%BC%8C50%0A%EF%BC%881%EF%BC%89%EF%BC%9A9-15%EF%BC%8EMCGLYNN%E2%80%83J%EF%BC%8CHEYBOER%E2%80%83M%EF%BC%8ESuccessful%E2%80%83treatment%E2%80%83%0Aof%E2%80%83%20radiation-induced%E2%80%83vaginal%E2%80%83soft%E2%80%83tissue%E2%80%83%20radionecrosis%E2%80%83%0Awith%E2%80%83%E2%80%83HBO2%EF%BC%BBJ%EF%BC%BD%EF%BC%8EUndersea%E2%80%83Hyperb%E2%80%83Med%EF%BC%8C2023%EF%BC%8C50%0A%EF%BC%881%EF%BC%89%EF%BC%9A9-15%EF%BC%8E
27、VARYT%C4%96%E2%80%83G%EF%BC%8CBARTKEVI%C4%8CIEN%C4%96%E2%80%83D%EF%BC%8EPelvic%E2%80%83%20radiation%E2%80%83%0Atherapy%E2%80%83induced%E2%80%83vaginal%E2%80%83stenosis%EF%BC%9AA%E2%80%83%20review%E2%80%83of%E2%80%83current%E2%80%83%0Amodalities%E2%80%83and%E2%80%83recent%E2%80%83treatment%E2%80%83advances%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMedicina%EF%BC%88Kaunas%EF%BC%89%EF%BC%8C2021%EF%BC%8C57%EF%BC%884%EF%BC%89%EF%BC%9A336%EF%BC%8EVARYT%C4%96%E2%80%83G%EF%BC%8CBARTKEVI%C4%8CIEN%C4%96%E2%80%83D%EF%BC%8EPelvic%E2%80%83%20radiation%E2%80%83%0Atherapy%E2%80%83induced%E2%80%83vaginal%E2%80%83stenosis%EF%BC%9AA%E2%80%83%20review%E2%80%83of%E2%80%83current%E2%80%83%0Amodalities%E2%80%83and%E2%80%83recent%E2%80%83treatment%E2%80%83advances%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AMedicina%EF%BC%88Kaunas%EF%BC%89%EF%BC%8C2021%EF%BC%8C57%EF%BC%884%EF%BC%89%EF%BC%9A336%EF%BC%8E
28、PERRONE%E2%80%83A%E2%80%83M%EF%BC%8CTESEI%E2%80%83M%EF%BC%8CFERIOLI%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AResults%E2%80%83of%E2%80%83a%E2%80%83phase%E2%80%83I-II%E2%80%83study%E2%80%83on%E2%80%83laser%E2%80%83therapy%E2%80%83for%E2%80%83vaginal%E2%80%83%0Aside%E2%80%83%20effects%E2%80%83%20after%E2%80%83%20radiotherapy%E2%80%83for%E2%80%83%20cancer%E2%80%83%20of%E2%80%83%20uterine%E2%80%83%0Acervix%E2%80%83or%E2%80%83endometrium%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancers%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2020%EF%BC%8C12%EF%BC%886%EF%BC%89%EF%BC%9A1639%EF%BC%8EPERRONE%E2%80%83A%E2%80%83M%EF%BC%8CTESEI%E2%80%83M%EF%BC%8CFERIOLI%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AResults%E2%80%83of%E2%80%83a%E2%80%83phase%E2%80%83I-II%E2%80%83study%E2%80%83on%E2%80%83laser%E2%80%83therapy%E2%80%83for%E2%80%83vaginal%E2%80%83%0Aside%E2%80%83%20effects%E2%80%83%20after%E2%80%83%20radiotherapy%E2%80%83for%E2%80%83%20cancer%E2%80%83%20of%E2%80%83%20uterine%E2%80%83%0Acervix%E2%80%83or%E2%80%83endometrium%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECancers%EF%BC%88Basel%EF%BC%89%EF%BC%8C%0A2020%EF%BC%8C12%EF%BC%886%EF%BC%89%EF%BC%9A1639%EF%BC%8E
29、王嘉贤,刘北梅,郑赛云,等.生殖系统肿瘤健康教育干预方式对社区已婚女性认知与健康行为的影响[J].现代医院,2021,21(8):1261-1263,1267.王嘉贤,刘北梅,郑赛云,等.生殖系统肿瘤健康教育干预方式对社区已婚女性认知与健康行为的影响[J].现代医院,2021,21(8):1261-1263,1267.
30、刘兴华.正念干预专家共识[J].中华行为医学与脑科学杂志,2019,28(9):771-777.刘兴华.正念干预专家共识[J].中华行为医学与脑科学杂志,2019,28(9):771-777.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录